SOURCES SOUGHT
66 -- Thrombo Elastograph Hemostasis Analyzer
- Notice Date
- 8/22/2014
- Notice Type
- Sources Sought
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 3900 NCTR Road, HFT-320, Bldg 50 | Rm 421, Jefferson, Arkansas, 72079, United States
- ZIP Code
- 72079
- Solicitation Number
- FDA-SS-1140628
- Point of Contact
- Daniel Weingarten, Phone: 240-402-7625
- E-Mail Address
-
Daniel.Weingarten@fda.hhs.gov
(Daniel.Weingarten@fda.hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- General Information: Document Type: Sources Sought - FDA-SS-1140628 Release Date: August 22, 2014, 2014 Response Date: August 27, 2014 at 12:00pm EST via email to Daniel.Weingarten@fda.hhs.gov Contracting Office Address: Food and Drug Administration, 5630 Fisher Lane, Rockville, Maryland 20857; Attn: Daniel Weingarten, Contract Specialist Description of Services/Supplies: Thrombo-Elastograph Hemostasis Analyzer CONTRACTING OFFICE U.S. Department of Health and Human Services (DHHS) Food and Drug Administration Agency (FDA) / Office of Acquisitions and Grants Services (OAGS) DESCRIPTION This is a SOURCES SOUGHT NOTICE to determine the availability and capability of small businesses (including certified 8(a), Small Disadvantaged, and HUBZone firms; veteran and service-disabled veteran-owned small businesses, and women-owned small businesses) for the purchase of a Thrombo-Elastograph Hemostasis Analyzer. The Contractor's capability statement shall demonstrate the company's ability to provide the following requirement. The analyzer must meet the following Salient Characteristics: The hemostasis analyzer system must conform to the following specifications: 1. Analyzing capacity: The instrument must be able to test on whole blood and measure the following parameter: (i) the rate of blood clot formation, (ii) the strength and stability of the clot, (iii) clot breakdown (fibrinolysis) process, (iv) the effects of platelets, coagulation factors, and cellular interactions on clot formation, (v) platelet functions. 2. Test fluid: must be able to test on whole blood and plasma 3. Number of testing channels: the instrument must have at least 2 independent testing channels to enable a side-by-side comparison between a subject and a control sample. 4. Blood sample volume: no more than 0.5 ml of blood should be necessary for each test. 5. Temperature control: The test temperate for each test channel should be adjustable and can maintain at a desirable temperature from room temperature to physiological body temperature (e.g. 23ºC to 37 ºC). 6. Software: The system should include computer software that produces both quantitative parameters and a graphical representation which allows the evaluation of the different phases of clotting formation and breakdown processes. The soft should be compatible with PC Windows operation system (which is currently used in the lab). 7. Portability: the instrument should weigh less than 40 lbs. 8. Power requirements: 110-120 VAC, 50-60 Hz. Responses to this notice must be limited to 5 pages, and must include: 1. Company name, mailing address, e-mail address, telephone and FAX numbers, website address (if available), and the name, telephone number, and e-mail address of a point of contact having the authority and knowledge to clarify responses with Government representatives. 2. A description of the product that the company could provide adhering to the salient characteristics listed. 3. Business size for NAICS 334516 (size standard of 500 employees) and status, if qualified as an 8(a) firm (must be certified by SBA), Small Disadvantaged Business (must be certified by SBA), Woman-Owned Small Business, HUBZone firm (must be certified by SBA), and/or Service-Disabled Veteran-Owned Small Business (must be listed in the VetBiz Vendor Information Pages). 4. DUNS number, CAGE Code, Tax Identification Number, and company structure (Corporation, LLC, partnership, joint venture, etc.). Companies also must be registered in the System for Award Management (SAM) to be considered as potential sources. 5. If applicable, identification of the firm's GSA Schedule contract(s) by Schedule number and contract number and SINs that are applicable to this potential requirement are also requested. 6. If the company has a Government approved accounting system, please identify the agency that approved the system. 7. Past performance references with points of contact and telephone numbers. At least three references are requested. Please submit copies of any documentation such as letters or certificates to indicate the firm's status (see item #3, above). Teaming arrangements are acceptable, and the information required above on the company responding to this announcement, should also be provided for each entity expected to be teammates of the respondent for performance of this work. To the maximum extent possible, please submit non-proprietary information. Any proprietary information submitted should be identified as such and will be properly protected from disclosure. This notice is for planning purposes only, and does not constitute an Invitation for Bids, Request for Proposals, Solicitation, Request for Quotes, or an indication the Government will contract for the items contained in this announcement. This request is not to be construed as a commitment on the part of the Government to award a contract, nor does the Government intend to pay for any information submitted as a result of this request. The Government will not reimburse respondents for any cost associated with submission of the information being requested or reimburse expenses incurred to interested parties for responses to this announcement. Responses to this notice must be received via email to Contract Specialist Daniel Weingarten at Daniel.Weingarten@fda.hhs.gov no later than 12:00 PM Eastern time on Wednesday, August 27, 2014 for consideration. Responses to this announcement will not be returned, nor any ensuing discussions or debriefings of any responses. However, information obtained as a result of this announcement may be reflected in the subsequent solicitation, and the FDA may contact one or more respondents for clarifications and to enhance the Governments understanding. This announcement is Government market research, and may result in revisions in both its requirements and its acquisition strategy based on industry responses.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/NCTR/FDA-SS-1140628/listing.html)
- Place of Performance
- Address: 10903 New Hampshire Ave, Building 66, Silver Spring, Maryland, 20993, United States
- Zip Code: 20993
- Zip Code: 20993
- Record
- SN03477006-W 20140824/140822235250-1d11b9303f37a3881558b02261d6da54 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |